目的:研究LASIK术后应用5g/L氯替泼诺混悬滴眼液的临床治疗效果。方法:采用随机对照研究,常规行双眼LASIK手术80例分为试验组(氯替泼诺组)和对照组(氟米龙组),试验组术后1d开始使用5g/L氯替泼诺滴眼液(露达舒)4次/d,每隔1wk递减1次,共用4wk,对照组术后1d开始使用1g/L氟米龙滴眼液4次/d,每隔1wk递减1次,共用4wk,两组术后次日均滴左氧氟沙星眼药水,4次/d,持续1wk停药,观察指标包括:术后1,7d;1,3mo裸眼视力,屈光度,弥漫性角膜基质炎(DLK),眼压方面及眼部刺激症状,采用t检验进行统计学分析。结果:两组术后眼压与术前眼压相比差异有显著统计学意义,所有术眼术后眼压水平均低于术前,在眼部疼痛感,异物感,裸眼视力,等效球镜度,DLK方面两组差异均无统计学意义。结论:应用5g/L氯替泼诺可有效抑制LASIK术后炎性反应,与传统的类固醇滴眼液相比,升高眼压的明显降低,可减少激素性高眼压的出现,并可有效预防DLK,获得预期临床效果。

AIM:To compare the visual refractive outcome and complication of laser in situ keratomileusis (LASIK) treated with 5g/L loteprednol etabonate and 1g/L fluorometholone ophthalmic suspension after operation. ·METHODS:Totally 160 consecutive eyes that received 5g/L loteprednol etabonate ophthalmic suspension(group A) and 1g/L fluorometholone ophthalmic suspension (group B) after LASIK were reviewed. Manifest refrac-tion,uncorrected visual acuity(UCVA),best spectacle-corrected visual acuity (BSCVA),and intraocular pres-sure (IOP) were recorded before and 1 day,1 week,1 month,3 months after treatment.Diffuse lamellar keratitis (DLK),postoperative complications,and frequency of retreatments were observed. ·RESULTS:There was no difference in manifest refraction,UCVA,BSCVA and DLK after operation between two groups. Preoperatively IOP didn’t differ significantly between two groups. IOP in group A and B were 13.3±3.5mmHg and 16.4±4.9mmHg respectively 3 months after operation. IOP in group A was lower significantly than the later. ·CONCLUSION:Loteprednol etabonate ophthalmic suspension 5g/L can suppress the inflammation response caused by LASIK effectively. Compared with traditional steroid suspension,5g/L Etabonate ophthalmic suspen-sion can obviously reduce occurrence of high IOP.

R779.63